ELTX
Elicio Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Elicio Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005, a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P), a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines, adjuvants, and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005, a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P), a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines, adjuvants, and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Elicio Therapeutics, Inc.
1.54
+0.02 · +1.31%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Elicio Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Elicio Therapeutics, Inc..
Tall tick = annual report · Source: EDGAR
—
—
Bull2
Bear1
| Manager | Value | % base | |
|---|---|---|---|
| Knoll | $4.7M | 20.89% | +92.10% |
| BlackRockindex-like | $3.0M | 13.20% | +1413.93% |
| Caption | $2.3M | 10.06% | new |
| Vanguardindex-like | $2.2M | 9.86% | +10.32% |
| Ikarian Capital | $1.2M | 5.41% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Knoll | $4.7M | 20.89% | +92.10% |
| BlackRockindex-like | $3.0M | 13.20% | +1413.93% |
| Caption | $2.3M | 10.06% | new |
| Vanguardindex-like | $2.2M | 9.86% | +10.32% |
| Ikarian Capital | $1.2M | 5.41% | new |
Expected move
Inputsspot 1.52exp Nov 20ATM strike 2.5ATM straddle 1.10IV 207%